Author's Reply to Perera et al.: A Commentary on "An Early Cost-Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom".
Saved in:
| Title: | Author's Reply to Perera et al.: A Commentary on "An Early Cost-Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom". |
|---|---|
| Authors: | Bretos-Azcona PE; Market Access & HEOR Consulting, Fortrea, London, UK., Wallace M; Market Access & HEOR Consulting, Fortrea, London, UK., Jootun M; Market Access & HEOR Consulting, Fortrea, London, UK., Veljanoska E; Market Access & HEOR Consulting, Fortrea, London, UK., Agirrezabal I; Market Access & HEOR Consulting, Fortrea, London, UK., Szende A; Market Access & HEOR Consulting, Fortrea, London, UK. agota.szende@fortrea.com. |
| Source: | Clinical drug investigation [Clin Drug Investig] 2025 Jul; Vol. 45 (7), pp. 435-438. Date of Electronic Publication: 2025 May 09. |
| Publication Type: | Letter; Comment |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1918 (Electronic) Linking ISSN: 11732563 NLM ISO Abbreviation: Clin Drug Investig Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| ISSN: | 1179-1918 |
|---|---|
| DOI: | 10.1007/s40261-025-01443-w |
